Currently, microsatellite instability is the only molecular factor used in clinical decision-making for the management of colon cancer. Mismatch repair (MMR)-deficiency is more common in stage II tumors as compared to stage III tumors. MMR-deficient tumors are characterized by high frequency microsatellite instability (MSI). MMR-deficiency appears to be both a prognostic biomarker (associated with a lower recurrence risk in patients with stage II colon cancer) and a predictive biomarker (associated with less benefit, or even harm, from adjuvant single agent fluoropyrimidine chemotherapy). In this study, the CDX2-negative, ALCAM-positive subgroup was characterized by only partial overlap with tumors defined by microsatellite instability or TP53 mutations. How does this finding affect our interpretation of CDX2 as a prognostic and predictive marker?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.